Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Rilonacept

EU orphan designation number: EU/3/07/456   
Active ingredient: Rilonacept
Indication: Treatment of cryopirin-associated periodic syndromes (Familial Cold Urticaria Syndrome (FCUS), Muckle-Wells Syndrome (MWS), and Neonatal Onset Multisystem Inflammatory Disease (NOMID), also known as Chronic Infantile Neurological Cutaneous Articular Syndrome (CINCA)
Sponsor: Regeneron UK Limited
40 Bank Street, Canary Wharf, London E14 5DS, United Kingdom
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Rilonacept Regeneron on 23/10/2009 with the number EU/1/09/582

   Public summary of scientific opinion     EPAR

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
12/07/2007 Centralised Orphan - Designation EMEA/OD/016/07 (2007)3436 of 10/07/2007